Marlen C. Lauffer

412 total citations · 1 hit paper
11 papers, 199 citations indexed

About

Marlen C. Lauffer is a scholar working on Molecular Biology, Genetics and Genetics. According to data from OpenAlex, Marlen C. Lauffer has authored 11 papers receiving a total of 199 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Genetics and 2 papers in Genetics. Recurrent topics in Marlen C. Lauffer's work include Neurogenetic and Muscular Disorders Research (6 papers), CRISPR and Genetic Engineering (3 papers) and RNA Research and Splicing (3 papers). Marlen C. Lauffer is often cited by papers focused on Neurogenetic and Muscular Disorders Research (6 papers), CRISPR and Genetic Engineering (3 papers) and RNA Research and Splicing (3 papers). Marlen C. Lauffer collaborates with scholars based in Netherlands, Germany and United States. Marlen C. Lauffer's co-authors include Willeke van Roon‐Mom, Annemieke Aartsma‐Rus, Judith Niesen, Melanie Schoof, Ulrich Schüller, Rebecca Schüle, Christine L. E. Siezen, Daniela Indenbirken, Matthis Synofzik and Holm Graeßner and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Investigation and SHILAP Revista de lepidopterología.

In The Last Decade

Marlen C. Lauffer

10 papers receiving 196 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders

2024 129 citations Marlen C. Lauffer, Willeke van Roon‐Mom et al. SHILAP Revista de lepidopterología profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marlen C. Lauffer Netherlands	5	148	47	30	11	11	11	199
Thomas Smol France	10	129 0.9×	70 1.5×	36 1.2×	13 1.2×	17 1.5×	34	224
Siddaramappa J. Patil India	7	89 0.6×	71 1.5×	29 1.0×	17 1.5×	15 1.4×	24	165
Badam Enkhmandakh United States	11	200 1.4×	60 1.3×	24 0.8×	13 1.2×	25 2.3×	23	334
Birutė Burnytė Lithuania	7	103 0.7×	70 1.5×	11 0.4×	18 1.6×	10 0.9×	28	194
Mohammad A. Al–Muhaizea Saudi Arabia	10	112 0.8×	32 0.7×	45 1.5×	19 1.7×	19 1.7×	29	191
Volkan Okur United States	9	117 0.8×	112 2.4×	13 0.4×	16 1.5×	15 1.4×	15	205
Dhanya Lakshmi Narayanan India	10	135 0.9×	88 1.9×	17 0.6×	19 1.7×	13 1.2×	42	261
Mullin H.C. Yu Hong Kong	8	87 0.6×	114 2.4×	24 0.8×	12 1.1×	18 1.6×	15	188
Isabella Rau Germany	6	138 0.9×	97 2.1×	19 0.6×	12 1.1×	17 1.5×	9	236
Naveed Wasif Pakistan	11	202 1.4×	101 2.1×	14 0.5×	14 1.3×	13 1.2×	30	322

Countries citing papers authored by Marlen C. Lauffer

Since Specialization

Citations

This map shows the geographic impact of Marlen C. Lauffer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marlen C. Lauffer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marlen C. Lauffer more than expected).

Fields of papers citing papers by Marlen C. Lauffer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marlen C. Lauffer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marlen C. Lauffer. The network helps show where Marlen C. Lauffer may publish in the future.

Co-authorship network of co-authors of Marlen C. Lauffer

This figure shows the co-authorship network connecting the top 25 collaborators of Marlen C. Lauffer. A scholar is included among the top collaborators of Marlen C. Lauffer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marlen C. Lauffer. Marlen C. Lauffer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Belgrad, Jillian, Erin M. McConnell, Simon Léonard, et al.. (2025). The N=1 Collaborative: advancing customized nucleic acid therapies through collaboration and data sharing. Nucleic Acids Research. 53(8). 3 indexed citations

Lauffer, Marlen C., Kimberly Amburgey, Danique Beijer, et al.. (2025). Screening rare genetic diagnoses for amenability to bespoke antisense oligonucleotide therapy development: A retrospective cohort study. Genetics in Medicine. 28(1). 101597–101597.

Ding, Mei, Michaela Chocholoušková, Cheen Fei Chin, et al.. (2025). SPNS1 variants cause multiorgan disease and implicate lysophospholipid transport as critical for mTOR-regulated lipid homeostasis. Journal of Clinical Investigation. 135(17). 1 indexed citations

Lauffer, Marlen C., et al.. (2024). Practical Recommendations for the Selection of Patients for Individualized Splice-Switching ASO-Based Treatments. Human Mutation. 2024. 1–13. 2 indexed citations

Aartsma‐Rus, Annemieke, Rob W.J. Collin, Ype Elgersma, Marlen C. Lauffer, & Willeke van Roon‐Mom. (2024). Joining forces to develop individualized antisense oligonucleotides for patients with brain or eye diseases: the example of the Dutch Center for RNA Therapeutics. PubMed. 5. 931183225–931183225. 5 indexed citations

Roon‐Mom, Willeke van, et al.. (2024). Treatability of the KMT2-Associated Neurodevelopmental Disorders Using Antisense Oligonucleotide-Based Treatments. Human Mutation. 2024. 1–17. 1 indexed citations

Lauffer, Marlen C., et al.. (2024). Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. SHILAP Revista de lepidopterología. 4(1). 6–6. 129 indexed citations breakdown →

Aartsma‐Rus, Annemieke, Willeke van Roon‐Mom, Marlen C. Lauffer, et al.. (2023). Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerations. RNA. 29(4). 446–454. 17 indexed citations

Lauffer, Marlen C.. (2021). Organ-on-a-chip technologies to study neuromuscular disorders: possibilities, limitations, and future hopes. Medizinische Genetik. 33(3). 261–267. 2 indexed citations

10.

Schoof, Melanie, et al.. (2020). The basic helix‐loop‐helix transcription factor TCF4 impacts brain architecture as well as neuronal morphology and differentiation. European Journal of Neuroscience. 51(11). 2219–2235. 21 indexed citations

11.

Lauffer, Marlen C., Michael Bockmayr, Michael Spohn, et al.. (2019). TCF4 (E2-2) harbors tumor suppressive functions in SHH medulloblastoma. Acta Neuropathologica. 137(4). 657–673. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact